The Role of β-Blockers in Melanoma.
Adrenaline
Melanoma
Noradrenaline
Propranolol
β-adrenoceptors
Journal
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
ISSN: 1557-1904
Titre abrégé: J Neuroimmune Pharmacol
Pays: United States
ID NLM: 101256586
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
01
05
2019
accepted:
15
08
2019
pubmed:
5
9
2019
medline:
28
5
2021
entrez:
5
9
2019
Statut:
ppublish
Résumé
Melanoma is one of the most aggressive and less chemotherapy-responsive human cancers, representing a major public health issue worldwide. The early diagnosis still represents the best approach in order to reduce mortality, especially in advanced stages. Preclinical evidence, collected through several in vitro and in vivo models, has been accumulating about the pathophysiological involvement of β-adrenoceptors in melanoma progression. This involvement has been paralleled by the evidence that drugs blocking β-adrenoceptors (β-blockers) may have a relevant role in the treatment of melanoma and in the prevention of its progression. β-blockers are a class of drugs extensively used in clinical practice, not limited to cardiovascular therapeutics. Evidence collected through retrospective and prospective observational studies suggests that treatment with β-blockers, mainly propranolol, is able to delay melanoma progression. Although conclusive evidence is still lacking, current knowledge proposes β-blockers as an opportunity for antitumor treatment in melanoma. Clinical trials are needed in order to prove their claimed efficacy. Graphical Abstract.
Identifiants
pubmed: 31482435
doi: 10.1007/s11481-019-09876-9
pii: 10.1007/s11481-019-09876-9
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Receptors, Adrenergic, beta
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
17-26Références
Melanoma Res. 2017 Jun;27(3):268-270
pubmed: 28346289
Brain Behav Immun. 2009 Feb;23(2):267-75
pubmed: 18996182
Oncotarget. 2017 Nov 25;9(1):802-811
pubmed: 29416656
Arch Intern Med. 2011 Apr 25;171(8):779-81
pubmed: 21518948
Oncotarget. 2016 Oct 18;7(42):68314-68327
pubmed: 27582542
Melanoma Res. 2016 Dec;26(6):609-615
pubmed: 27603551
Cell Signal. 2015 May;27(5):997-1007
pubmed: 25703025
J Immunol. 2010 Mar 1;184(5):2449-57
pubmed: 20124103
Oxid Med Cell Longev. 2018 Nov 13;2018:6816508
pubmed: 30538804
Mayo Clin Proc. 2013 Nov;88(11):1196-203
pubmed: 24182700
Stem Cells Transl Med. 2016 Jan;5(1):45-55
pubmed: 26574555
J Anesth. 2016 Jun;30(3):365-8
pubmed: 27052331
Br J Dermatol. 1990 Aug;123(2):163-70
pubmed: 1976019
J Natl Cancer Inst. 1951 Oct;12(2):399-421
pubmed: 14889251
Eur J Cancer. 2013 Dec;49(18):3863-71
pubmed: 23942335
Mol Pharmacol. 1994 Mar;45(3):490-9
pubmed: 7908406
Dermatol Res Pract. 2010;2010:483493
pubmed: 20585601
Br J Dermatol. 2014 Apr;170(4):930-8
pubmed: 24593055
Cancer Biol Ther. 2010 Jul 1;10(1):19-29
pubmed: 20424515
Carcinogenesis. 1989 Sep;10(9):1753-5
pubmed: 2569945
Cancer Res. 2017 Oct 15;77(20):5639-5651
pubmed: 28819022
Oncotarget. 2016 Oct 25;7(43):70936-70947
pubmed: 27708216
J Natl Cancer Inst. 1962 Jan;28:211-29
pubmed: 13902917
Cancer Treat Rev. 2016 Jun;47:1-11
pubmed: 27179912
J Invest Dermatol. 2015 Feb;135(2):525-531
pubmed: 25178102
J Eur Acad Dermatol Venereol. 2018 Mar;32(3):363-371
pubmed: 28850731
Naunyn Schmiedebergs Arch Pharmacol. 2015 Dec;388(12):1317-31
pubmed: 26285646
J Natl Cancer Inst. 1961 Dec;27:1465-91
pubmed: 13902916
Stress. 2016 Jul;19(4):419-28
pubmed: 27398826
Amino Acids. 2013 Jul;45(1):55-71
pubmed: 22160285
Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2273-9
pubmed: 21933972
N Engl J Med. 2008 Jun 12;358(24):2649-51
pubmed: 18550886
Oncotarget. 2016 Nov 22;7(47):77825-77837
pubmed: 27788481
J Exp Clin Cancer Res. 2005 Sep;24(3):387-95
pubmed: 16270525
Oncoimmunology. 2017 Dec 21;7(3):e1405205
pubmed: 29399407
Nat Med. 2006 Aug;12(8):939-44
pubmed: 16862152
Public Health. 2017 Aug;149:138-148
pubmed: 28641155
Lab Invest. 2013 Mar;93(3):279-90
pubmed: 23318885
Br J Pharmacol. 2005 Feb;144(3):317-22
pubmed: 15655528
Acta Derm Venereol. 2015 May;95(5):516-24
pubmed: 25520039
Science. 2017 Oct 20;358(6361):321-326
pubmed: 29051371
Mol Carcinog. 2018 Aug;57(8):997-1007
pubmed: 29626349
Oncotarget. 2015 Mar 10;6(7):4615-32
pubmed: 25474135
Oncoscience. 2017 Aug 23;4(7-8):95-105
pubmed: 28966942
J Transl Med. 2013 Mar 22;11:72
pubmed: 23517603
Onco Targets Ther. 2018 Aug 20;11:4913-4944
pubmed: 30174436
PLoS One. 2013 Nov 06;8(11):e78175
pubmed: 24223137
Br J Anaesth. 2018 Jul;121(1):45-57
pubmed: 29935594
J Mol Med (Berl). 2013 Dec;91(12):1407-19
pubmed: 23907236
Semin Cancer Biol. 2013 Dec;23(6 Pt B):533-42
pubmed: 24012659
Curr Drug Deliv. 2013 Feb;10(1):64-6
pubmed: 22998044
Ann Surg. 2011 Apr;253(4):798-810
pubmed: 21475023
Cancer. 1994 Aug 15;74(4 Suppl):1453-7
pubmed: 8062175
JAMA Oncol. 2018 Feb 8;4(2):e172908
pubmed: 28973254
Cancer Res. 1966 Jul;26(7):1420-4
pubmed: 5911584
Br J Pharmacol. 2017 Jan;174(2):139-149
pubmed: 27792834
Eur Heart J. 2004 Aug;25(15):1341-62
pubmed: 15288162
Endocr Regul. 2003 Jun;37(2):69-80
pubmed: 12932192
Br J Cancer. 2013 Jun 25;108(12):2485-94
pubmed: 23695022
J Cancer Res Clin Oncol. 2017 Feb;143(2):275-291
pubmed: 27709364